Is Transcode Therapeutics Stock a Good Investment?
Transcode Therapeutics Investment Advice | RNAZ |
- Examine Transcode Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Transcode Therapeutics' leadership team and their track record. Good management can help Transcode Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Transcode Therapeutics' business and its evolving consumer preferences.
- Compare Transcode Therapeutics' performance and market position to its competitors. Analyze how Transcode Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Transcode Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Transcode Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Transcode Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Transcode Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Modest | Details | |
Volatility | Moderately volatile | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | About Average | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Transcode Therapeutics Stock
Researching Transcode Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company has price-to-book ratio of 0.81. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Transcode Therapeutics recorded a loss per share of 792.4. The entity had not issued any dividends in recent years. The firm had 1:28 split on the 15th of May 2025.
To determine if Transcode Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Transcode Therapeutics' research are outlined below:
| Transcode Therapeutics is way too risky over 90 days horizon | |
| Transcode Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (16.75 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Transcode Therapeutics currently holds about 13.45 M in cash with (13.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.04. | |
| Transcode Therapeutics has a frail financial position based on the latest SEC disclosures |
Transcode Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Transcode Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Transcode Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 29th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Transcode Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Transcode Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2022-05-16 | 2022-03-31 | -0.25 | -0.22 | 0.03 | 12 | ||
2022-08-15 | 2022-06-30 | -0.3 | -0.36 | -0.06 | 20 | ||
2022-11-14 | 2022-09-30 | -0.4 | -0.33 | 0.07 | 17 | ||
2023-11-13 | 2023-09-30 | -1.5 | -1.68 | -0.18 | 12 | ||
2025-04-15 | 2025-03-31 | -0.37 | -9.7 | -9.33 | 2521 | ||
2024-04-01 | 2024-03-31 | -10.8 | -22.84 | -12.04 | 111 | ||
2024-03-29 | 2023-12-31 | -356.4004 | -627.3306 | -270.9302 | 76 | ||
2024-11-18 | 2024-09-30 | -452.7603 | -147.8401 | 304.9202 | 67 |
Know Transcode Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Transcode Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Transcode Therapeutics backward and forwards among themselves. Transcode Therapeutics' institutional investor refers to the entity that pools money to purchase Transcode Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Fmr Inc | 2025-03-31 | 25.0 | Bank Of America Corp | 2025-03-31 | 6.0 | Captrust Financial Advisors | 2024-12-31 | 0.0 | Jane Street Group Llc | 2024-12-31 | 0.0 | Sheets Smith Wealth Management | 2024-12-31 | 0.0 | Private Capital Management Llc | 2024-12-31 | 0.0 | Geode Capital Management, Llc | 2024-12-31 | 0.0 | Anson Funds Management Lp | 2025-03-31 | 1.5 M | Ubs Group Ag | 2025-03-31 | 263.9 K | Sabby Management Llc | 2025-03-31 | 229.1 K | Warberg Asset Management Llc | 2025-03-31 | 50 K |
Transcode Therapeutics' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 8.29 M.Market Cap |
|
Transcode Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.30) | (2.41) | |
| Return On Capital Employed | (3.46) | (3.64) | |
| Return On Assets | (2.30) | (2.41) | |
| Return On Equity | 8.30 | 8.71 |
Determining Transcode Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Transcode Therapeutics is a good buy. For example, gross profit margin measures Transcode Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Transcode Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Transcode Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Transcode Therapeutics. Check Transcode Therapeutics' Beneish M Score to see the likelihood of Transcode Therapeutics' management manipulating its earnings.
Evaluate Transcode Therapeutics' management efficiency
Transcode Therapeutics has return on total asset (ROA) of (0.9484) % which means that it has lost $0.9484 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.4299) %, meaning that it created substantial loss on money invested by shareholders. Transcode Therapeutics' management efficiency ratios could be used to measure how well Transcode Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 8.71 in 2025, whereas Return On Tangible Assets are likely to drop (2.41) in 2025. At this time, Transcode Therapeutics' Net Tangible Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 287.2 K in 2025, whereas Total Assets are likely to drop slightly above 7 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (5.67) | (5.95) | |
| Tangible Book Value Per Share | (5.67) | (5.95) | |
| Enterprise Value Over EBITDA | (1.10) | (1.15) | |
| Price Book Value Ratio | (11.66) | (12.24) | |
| Enterprise Value Multiple | (1.10) | (1.15) | |
| Price Fair Value | (11.66) | (12.24) | |
| Enterprise Value | 17.8 M | 16.9 M |
Evaluating the management effectiveness of Transcode Therapeutics allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Transcode Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Beta 1.332 |
Basic technical analysis of Transcode Stock
As of the 21st of July, Transcode Therapeutics has the Coefficient Of Variation of 4469.1, risk adjusted performance of 0.0299, and Semi Deviation of 7.91. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Transcode Therapeutics, as well as the relationship between them.Transcode Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Transcode Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Transcode Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Transcode Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Transcode Therapeutics' Outstanding Corporate Bonds
Transcode Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Transcode Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Transcode bonds can be classified according to their maturity, which is the date when Transcode Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| TRANSCANADA PIPELINES LTD Corp BondUS893526DF78 | View | |
| TRANSCANADA PIPELINES LTD Corp BondUS893526DJ90 | View | |
| TRANSATLANTIC HLDGS INC Corp BondUS893521AB05 | View | |
| TRANSCONTINENTAL GAS PIPE Corp BondUS893574AB92 | View | |
| TRANSCONTINENTAL GAS PIPE Corp BondUS893574AH62 | View | |
| US893574AF07 Corp BondUS893574AF07 | View | |
| TRPCN 55 15 SEP 79 Corp BondUS89356BAE83 | View | |
| TRPCN 5875 15 AUG 76 Corp BondUS89356BAB45 | View |
Understand Transcode Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Transcode Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0299 | |||
| Market Risk Adjusted Performance | 0.1438 | |||
| Mean Deviation | 6.36 | |||
| Semi Deviation | 7.91 | |||
| Downside Deviation | 8.03 | |||
| Coefficient Of Variation | 4469.1 | |||
| Standard Deviation | 9.49 | |||
| Variance | 90.1 | |||
| Information Ratio | 0.0075 | |||
| Jensen Alpha | 0.0046 | |||
| Total Risk Alpha | (1.13) | |||
| Sortino Ratio | 0.0089 | |||
| Treynor Ratio | 0.1338 | |||
| Maximum Drawdown | 59.97 | |||
| Value At Risk | (17.50) | |||
| Potential Upside | 13.27 | |||
| Downside Variance | 64.49 | |||
| Semi Variance | 62.57 | |||
| Expected Short fall | (7.98) | |||
| Skewness | 0.8692 | |||
| Kurtosis | 4.54 |
| Risk Adjusted Performance | 0.0299 | |||
| Market Risk Adjusted Performance | 0.1438 | |||
| Mean Deviation | 6.36 | |||
| Semi Deviation | 7.91 | |||
| Downside Deviation | 8.03 | |||
| Coefficient Of Variation | 4469.1 | |||
| Standard Deviation | 9.49 | |||
| Variance | 90.1 | |||
| Information Ratio | 0.0075 | |||
| Jensen Alpha | 0.0046 | |||
| Total Risk Alpha | (1.13) | |||
| Sortino Ratio | 0.0089 | |||
| Treynor Ratio | 0.1338 | |||
| Maximum Drawdown | 59.97 | |||
| Value At Risk | (17.50) | |||
| Potential Upside | 13.27 | |||
| Downside Variance | 64.49 | |||
| Semi Variance | 62.57 | |||
| Expected Short fall | (7.98) | |||
| Skewness | 0.8692 | |||
| Kurtosis | 4.54 |
Consider Transcode Therapeutics' intraday indicators
Transcode Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Transcode Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Transcode Therapeutics Corporate Filings
| 15th of July 2025 Other Reports | ViewVerify | |
8K | 13th of June 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 14th of May 2025 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
10K | 30th of April 2025 An amendment to a previously filed Form 10-K | ViewVerify |
Transcode Stock media impact
There is far too much social signal, news, headlines, and media speculation about Transcode Therapeutics that are available to investors today. This information is accessible both publicly - through Transcode Therapeutics' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Transcode-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Transcode Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Transcode Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Transcode Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Transcode Therapeutics alpha.
Transcode Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Transcode Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Transcode Therapeutics Corporate Management
| RN MBA | Senior Operations | Profile | |
| Daniel MD | Chief Officer | Profile | |
| Anna Moore | Scientific CoFounder | Profile | |
| Calais Pharm | Executive Board | Profile | |
| Robert Dudley | CEO, CoFounder | Profile |
Additional Tools for Transcode Stock Analysis
When running Transcode Therapeutics' price analysis, check to measure Transcode Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transcode Therapeutics is operating at the current time. Most of Transcode Therapeutics' value examination focuses on studying past and present price action to predict the probability of Transcode Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transcode Therapeutics' price. Additionally, you may evaluate how the addition of Transcode Therapeutics to your portfolios can decrease your overall portfolio volatility.